Search "peptides for skin injection" and the results mix three very different things: clinic menus offering "peptide injections", research-peptide vials sold online, and approved aesthetic injectables that have nothing peptide about them. This page separates them. It counts what the research literature holds on injecting peptides for skin, reads FDA's drug and device records for where peptides actually appear in approved products, and sends the dose and compound questions to the pages that own them. It is not a guide to any injection.
The census: no trial injects a signal peptide for wrinkles
On 3 October 2026 we searched PubMed for any peptide term — including the tri-, tetra-, penta-, hexa- and oligo- prefixes that the bare word "peptide" misses, plus GHK, BPC-157 and thymosin beta — combined with an injection term (injection, injectable, intradermal, mesotherapy) and a skin-ageing term (wrinkle, photoaging, rejuvenation). It returned 34 records. We read every title, and the abstract where the title was unclear.
| What the record is | Count |
|---|---|
| A trial that injects a signal peptide into the skin for wrinkles or photoaging | 0 |
| An injection (botulinum toxin ×2, recombinant collagen ×1) followed by a peptide cream or serum on the skin | 3 |
| Trials of a botulinum toxin whose formula contains a peptide excipient | 2 |
| Laboratory studies, reviews, and papers that matched only on words (osteoarthritis, insect hormones, an insulin assay) | 29 |
The randomized-trial filter on the same search left 2: one of the collagen-plus-serum studies and one of the toxin trials. The same filter for hyaluronic-acid injections for wrinkles or folds returned 155, so the search works; the absence is real. The retracted-publication filter returned 0.
The peptide in the three combination studies goes on the skin, not into it. The trial evidence for peptides on skin is a topical literature, ranked on our peptides for skin page and explained on what peptides do for skin.
Where peptides appear in approved injectables
FDA's records show peptides in aesthetic medicine in two places, and neither is the one clinic menus suggest.
As an inactive ingredient. DAXXIFY (daxibotulinumtoxinA), approved for frown lines between the brows, is "formulated with a 35 amino acid peptide excipient (RTP004) that prevents surface adsorption and promotes thermal stability", per its label (effective 7 January 2026). Each vial contains 11.7 micrograms of it. The active ingredient is a 150 kDa botulinum toxin; the peptide keeps it stable in the vial. It is the reason two toxin trials appear in a peptide census, and it is not a peptide treatment.
As a pigment drug in an implant. Afamelanotide (Scenesse), the approved form of melanotan 1, is a peptide placed under the skin as a small implant. FDA approved it on 8 October 2019 for erythropoietic protoporphyria, a disorder that makes sunlight painful — not for tanning or ageing. Its record is on our afamelanotide page.
Not as a skin device. FDA's premarket-approval database held 32 records on 3 October 2026 whose device generic name contains "synthetic peptide". Every one is a bone-void filler or bone graft. None is a dermal filler or a skin product. The approved skin injectables — hyaluronic-acid gels including SKINVIVE, and the collagen stimulators such as Sculptra — are not peptides. Our skin boosters page sets out which booster materials hold US approval. The stimulators clinics inject instead are not peptides either; how Sculptra and Radiesse differ on the FDA record is set out separately.
What is sold for injection with skin claims
The peptides most often offered for injection with skin or "glow" claims are research compounds without an approval for any skin use:
| Compound | What the record holds | Where we cover it |
|---|---|---|
| GHK-Cu (copper peptide) | Cosmetic ingredient in creams; the one indexed randomized trial on skin, topical, was negative on its objective measures | Copper peptides |
| BPC-157 | On FDA's significant-safety-risk list for compounding (immunogenicity, impurities); July 2026 advisory committee reviewed it for ulcerative colitis only | The glow stack |
| TB-500 (thymosin beta-4 fragment) | Same FDA list; reviewed for wound healing | The glow stack |
| KLOW (four-peptide blend) | Med-spa marketing; no trial of the blend | KLOW peptide benefits |
| Melanotan II | Unapproved anywhere; tanning trials from the 1990s by injection; case reports of new moles and melanoma | Melanotan vials, read |
FDA's wording on BPC-157 is that compounded versions "may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization" — that is, the body may react to the injected peptide, and it is hard to establish what is in the vial. Appearance does not feature anywhere in that regulatory record.
Questions this page does not answer, and where they are answered
- Doses. Dose figures are outside this page. Peptifact reports published dose figures for individual compounds, with sources and dates, on its dosage pages.
- Tanning by injection. Covered on our page on melanotan injections and, for the needle-free version, tanning nasal spray.
- Polynucleotides and PDRN, which are injected in clinics outside the US: polynucleotides for skin and PDRN.
What would change this page
A registered, controlled trial injecting a defined peptide into the skin with a wrinkle or skin-quality endpoint; an FDA clearance or approval for a peptide skin product; or a published laboratory analysis of what injectable "skin peptides" sold online contain. None existed on 3 October 2026. Anyone weighing an injection of any kind should discuss it with a doctor who can confirm what is being injected and why.
Sources
- PubMed E-utilities, 3 October 2026: peptide-class terms (with prefixes, GHK, BPC-157, thymosin beta) AND injection terms AND wrinkle / photoaging / rejuvenation (34 records, all titles read); same with "randomized controlled trial"[pt] (2: PMIDs 42087486, 31791824); same with "Retracted Publication"[pt] (0); hyaluronic acid with filler or injection and wrinkle, fold or rejuvenation, "randomized controlled trial"[pt] (155).
- DAXXIFY (daxibotulinumtoxinA-lanm) prescribing information, openFDA label effective 7 January 2026, sections 1 and 11.
- FDA premarket-approval database (openFDA device/pma), 3 October 2026: generic name containing "synthetic peptide" (32 records).
- FDA, bulk drug substances that may present significant safety risks (page updated 22 April 2026), and the 23–24 July 2026 Pharmacy Compounding Advisory Committee agenda — as quoted and dated on our glow stack page.
- SCENESSE (afamelanotide) approval, 8 October 2019 — as dated on our afamelanotide page.